TABLE 2.

Planned analyses

			Interaction models
Description	Day	Adjustment	Age	Sex	Symptoms duration	WHO baseline
Primary analysis: comparison of CP vs Control (3 types)
1. WHO score: cum. prop. OR	14	Parsimonious${}^{\mathrm{a}}$	x	x	x	x
2. WHO 7‐10 (yes/no)	14	Parsimonious	x	x	x	x
Secondary analyses: comparison of CP vs Control (3 types)
3. WHO score: cum. prop. OR	14	Expanded${}^{\mathrm{b}}$	x	x	x	x
4. WHO 7‐10 (yes/no)	14	Expanded	x	x	x	x
5. WHO score: cum. prop. OR	28	Expanded	x	x	x	x
6. WHO 7‐10 (yes/no)	28	Expanded	x	x	x	x
Tertiary analyses: comparison of CP vs Control (3 types)
7. All‐cause mortality (yes/no)	14	Expanded	x	x	x	x
8. All‐cause mortality (yes/no)	28	Expanded	x	x	x	x
9. Time to discharge		Expanded	x	x	x	x
Tertiary analyses: dose‐response (comparison of no CP vs different number of CP units or levels of AB)
10. WHO score: cum. prop. OR	14	Expanded	x	x	x	x
11. WHO 7‐10 (yes/no)	14	Expanded	x	x	x	x
12. WHO score: cum. prop. OR	28	Expanded	x	x	x	x
13. WHO 7‐10 (yes/no)	28	Expanded	x	x	x	x
14. All‐cause mortality (yes/no)	14	Expanded	x	x	x	x
15. All‐cause mortality (yes/no)	28	Expanded	x	x	x	x
16. Time to discharge		Expanded	x	x	x	x

Abbreviations: AB, antibodies; CP, convalescent plasma; RCT, randomized clinical trial; WHO, World Health Organization.

^aParsimonious adjustment includes age, sex, WHO score at baseline, days since symptom onset and quarter when the patient was enrolled in the RCT.

^bExpanded adjustment also includes past medical history and concomitant medications at time of randomization.